Polypeptides of the IFNα-21 gene
AssigneeGenOdyssee SA
InventorJean-Louis Escary
Life of this patent
Estimating the term…
Abstract
Polynucleotides and polypeptides derived from the nucleotide sequence of the IFNα-21 gene comprising SNPs, and their therapeutic uses.
Claims64
An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a K179E SNP.
The composition of 2, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 5, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a K179E SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
The composition of 12, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 15, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a Q102K SNP.
The composition of 18, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 21, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a Q120K SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
The composition of 28, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 31, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a Q114H SNP.
The composition of 34, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 37, wherein said excipient is a buffer, aqueous vehicle, non-aqueous, vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a Q114H SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
The composition of 44, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 47, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a V127D SNP.
The composition of 50, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 53, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
An isolated polypeptide comprising an amino acid sequence at lens 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
- b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence of (a) or (b) comprises a V127D SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
The composition of 60, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
The pharmaceutical composition of 63, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
Dependencies are inferred from the claim text.